Theravance Biopharma (NASDAQ:TBPH) Downgraded by Zacks Research to Hold

Zacks Research lowered shares of Theravance Biopharma (NASDAQ:TBPH) from a strong-buy rating to a hold rating in a report published on Monday morning,Zacks reports.

A number of other research analysts also recently commented on TBPH. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. HC Wainwright cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and raised their target price for the stock from $15.00 to $17.00 in a research report on Tuesday, July 7th. BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. Weiss Ratings raised shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. Finally, JonesTrading downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. Eight equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $19.40.

Theravance Biopharma Stock Down 0.1%

Shares of NASDAQ:TBPH opened at $17.06 on Monday. The company has a market cap of $885.76 million, a P/E ratio of 16.89 and a beta of 0.25. The business has a fifty day simple moving average of $16.95 and a 200-day simple moving average of $16.49. Theravance Biopharma has a 52 week low of $13.08 and a 52 week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.18). Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%.The business had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $22.49 million. Sell-side analysts expect that Theravance Biopharma will post 1.56 earnings per share for the current fiscal year.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the transaction, the senior vice president directly owned 232,457 shares in the company, valued at $3,809,970.23. This trade represents a 5.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of Theravance Biopharma stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the transaction, the insider directly owned 9,174,453 shares in the company, valued at $155,965,701. This represents a 0.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is owned by company insiders.

Institutional Trading of Theravance Biopharma

Institutional investors have recently modified their holdings of the company. Quarry LP purchased a new position in Theravance Biopharma in the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd lifted its position in Theravance Biopharma by 107.4% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,411 shares in the last quarter. CIBC Private Wealth Group LLC grew its stake in Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 4,662 shares during the period. Tower Research Capital LLC TRC grew its stake in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares during the period. Finally, Virtus Advisers LLC acquired a new stake in shares of Theravance Biopharma in the fourth quarter worth $170,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.